Strategic Partnerships Leverage AIkido Pharma's active collaboration model with leading universities such as The University of Texas at Austin and University of Maryland Baltimore to position joint development opportunities, licensing deals, or co-funded research programs that could expand the company’s pipeline and accelerate preclinical/clinical progress.

Viral Platform Fit Capitalize on the broad-spectrum antiviral platform and ongoing oncology focus to present combined therapy or repurposing opportunities to biotech and pharma partners seeking dual oncology/virology pipelines or rapid-entry antiviral programs aligned with current global health priorities.

Financial Readiness Acknowledge recent financing activity and modest revenue scale to target strategic investors and collaborators for milestone-driven partnerships, licensing deals, or convertible financing that can fund expansion of their small-molecule pipeline and platform technologies.

Indicator from Leadership Utilize recent board appointments to signal governance and strategic pivot opportunities; propose executive briefings and collaboration discussions with prospective partners aligned to leadership’s vision and short-term milestones, enhancing credibility in BD conversations.

Niche Pipeline Valor Frame the company’s cancer targets in pancreatic and prostate domains along with antiviral breadth as a differentiator for specialty pharma seeking to bolster niche oncology portfolios or add antiviral capabilities to diversify risk and address unmet medical needs.